ADMS News and Press, Adamas Pharmaceuticals Inc. From 10/18/21

Potential deal in the works Aspen Technology materializes. Two deals with Contingent Value Rights announced last week. Navios Maritime Partners completed the acquisition of Navios Maritime Acquisition Corporation. For further details see: Merger Arbitrage Mondays: Emerso...

Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. The S&P 500 wrapped up its best week since July, closing at its highest level in a month, as a series of upside earnings reports from Wal...

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Adamas Pharmaceuticals, Inc. Announces Definitive Agreement to be Acquired by Supernus Pharmaceuticals, Inc” Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) surged ove...

Supernus Pharmaceuticals Inc ( NASDAQ: SUPN ) recently announced that it had entered a definitive contract to acquire Adamas Pharmaceuticals ( NASDAQ: ADMS ). Supernus is to purchase this company a tender offer that was worth about $8.10 per share. The aggregate was roug...

Gainers: Protagonist (NASDAQ:PTGX) +86%. Adamas (NASDAQ:ADMS) +75%. Flexion (NASDAQ:FLXN) +63%. Progenity (NASDAQ:PROG) +35%. Gaotu Techedu (NYSE:GOTU) +23%. U.S. Well Services (NASDAQ:USWS) +22%. Blue Apron (NYSE:APRN) +19%. EZFill (NASDAQ:EZFL) +18%. Ocular (NASDAQ:OCUL) +17%. Willamette Va...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investors in  Adamas Pharmaceuticals (NASDAQ: ADMS ) are off to a great week. The pharma play is getting picked up as part of an acquisition with biopharma company  Supernus (NASDAQ: SUPN ). The news thi...

Gainers: Protagonist Therapeutics (NASDAQ:PTGX) +82%, Adamas Pharmaceuticals (NASDAQ:ADMS) +74%, Flexion Therapeutics (NASDAQ:FLXN) +62%, Evelo Biosciences (NASDAQ:EVLO) +16%, Progenity (NASDAQ:PROG) +16%. Losers: Voyager Therapeutics (NASDAQ:VYGR)...

Protagonist Therapeutics (NASDAQ:PTGX) +89% after FDA removes clinical hold on rusfertide program Flexion Therapeutics (NASDAQ:FLXN) +73% Pacira Therapeutics acquires Flexion Therapeutics for $8.50 per share in cash plus one CVR Adamas Pharmaceuticals (NASDAQ:ADMS) +7...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Welcome back, traders! We’re kicking off the week with a look at the biggest pre-market stock market movers for Monday! Source: f11photo/Shutterstock.com There’s plenty of news moving stock today with ...

Acquisition of two marketed products diversifies and accelerates revenue and cash flow Expected to be significantly accretive in 2022 Potential synergies of $60 million to $80 million in year one due to strong overlap with existing infrastructure Total consideration up to $9...